Albemarle (ALB)
(Delayed Data from NYSE)
$100.84 USD
+0.91 (0.91%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $100.79 -0.05 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$100.84 USD
+0.91 (0.91%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $100.79 -0.05 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth F Momentum D VGM
Zacks News
Bear of the Day: Albemarle (ALB)
by Tracey Ryniec
This lithium producer is cheap.
Albemarle (ALB) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Albemarle (ALB) stood at $136.58, denoting a +0.55% change from the preceding trading day.
Albemarle Corporation (ALB) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Albemarle (ALB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
New Strong Sell Stocks for January 3rd
by Zacks Equity Research
ALB, FIHL and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 3, 2024.
Albemarle (ALB) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Albemarle (ALB) concluded the recent trading session at $146.89, signifying a +1.67% move from its prior day's close.
Brokers Suggest Investing in Albemarle (ALB): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Albemarle (ALB) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Wall Street Bulls Look Optimistic About Albemarle (ALB): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Albemarle (ALB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
New Strong Sell Stocks for December 7th
by Zacks Equity Research
ALB, CRGY and LOVE have been added to the Zacks Rank #5 (Strong Sell) List on December 7, 2023.
Albemarle Corporation (ALB) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Albemarle (ALB). This makes it worthwhile to examine what the stock has in store.
Why Is Albemarle (ALB) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Albemarle (ALB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy Albemarle (ALB) Ahead of Earnings?
by Zacks Equity Research
Albemarle (ALB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Albemarle (ALB) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Albemarle (ALB). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Investors Heavily Search Albemarle Corporation (ALB): Here is What You Need to Know
by Zacks Equity Research
Albemarle (ALB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Albemarle Corporation (ALB) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Albemarle (ALB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Albemarle (ALB) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Albemarle (ALB) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Albemarle's (ALB) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Albemarle (ALB) lags Q3 estimates despite higher volumes in the lithium business.
Albemarle (ALB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Albemarle (ALB) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Should You Buy Albemarle (ALB) Ahead of Earnings?
by Zacks Equity Research
Albemarle (ALB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Albemarle (ALB) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Albemarle (ALB) is likely to have benefited from higher lithium volumes and its cost-reduction actions in Q3 amid demand headwinds in specialties.
These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Eastman Chemical (EMN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Eastman Chemical (EMN) delivered earnings and revenue surprises of 1.38% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Albemarle (ALB) Stock Moves -0.08%: What You Should Know
by Zacks Equity Research
In the latest trading session, Albemarle (ALB) closed at $135.21, marking a -0.08% move from the previous day.
Analysts Estimate Avient (AVNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avient (AVNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albemarle (ALB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Albemarle (ALB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albemarle Corporation (ALB) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Albemarle (ALB). This makes it worthwhile to examine what the stock has in store.